Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IAP 0971

Next Previous
X
Search
Drug Profile

IAP 0971

Alternative Names: IAP-0971

Latest Information Update: 05 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SUNHO (China) BioPharmaceutical
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 receptor agonists; Natural killer cell stimulants; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 03 Sep 2024 SunHo BioPharmaceuticals plans a phase I/II trial for Solid tumours and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (SC) (NCT06581419)
  • 13 Feb 2024 SUNHO (China) BioPharmaceutical plans a phase I/II trial for Bladder cancer (Monotherapy, Combination therapy, Second-line therapy or greater) in February 2024 (Intravesicular) (NCT06255964)
  • 21 Jul 2023 Preliminary safety and efficacy data from a phase I trial in Solid Tumors released by SunHo BioPharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top